4.6 Article

Differential Activation of Wnt-β-Catenin Pathway in Triple Negative Breast Cancer Increases MMP7 in a PTEN Dependent Manner

期刊

PLOS ONE
卷 8, 期 10, 页码 -

出版社

PUBLIC LIBRARY SCIENCE
DOI: 10.1371/journal.pone.0077425

关键词

-

资金

  1. NIGMS NIH HHS [T32 GM008490] Funding Source: Medline

向作者/读者索取更多资源

Mutations of genes in tumor cells of Triple Negative subset of Breast Cancer (TNBC) deregulate pathways of signal transduction. The loss of tumor suppressor gene PTEN is the most common first event associated with basal-like subtype (Martins, De, Almendro, Gonen, and Park, 2012). Here we report for the first time that the functional upregulation of secreted-MMP7, a transcriptional target of Wnt-beta-catenin signature pathway in TNBC is associated to the loss of PTEN. We identified differential expression of mRNAs in several key-components genes, and transcriptional target genes of the Wnt-beta-catenin pathway (WP), including beta-catenin, FZD7, DVL1, MMP7, c-MYC, BIRC5, CD44, PPARD, c-MET, and NOTCH1 in FFPE tumors samples from TNBC patients of two independent cohorts. A similar differential upregulation of mRNA/protein for beta-catenin, the functional readout of WP, and for MMP7, a transcriptional target gene of beta-catenin was observed in TNBC cell line models. Genetic or pharmacological attenuation of beta-catenin by SiRNA or WP modulators (XAV939 and sulindac sulfide) and pharmacological mimicking of PTEN following LY294002 treatment downregulated MMP7 levels as well as enzymatic function of the secreted MMP7 in MMP7 positive PTEN-null TNBC cells. Patient data revealed that MMP7 mRNA was high in only a subpopulation of TNBC, and this subpopulation was characterized by a concurrent low expression of PTEN mRNA. In cell lines, a high expression of casein-zymograph-positive MMP7 was distinguished by an absence of functional PTEN. A similar inverse relationship between MMP7 and PTEN mRNA levels was observed in the PAM50 data set (a correlation coefficient of -0.54). The PAM50 subtype and outcome data revealed that the high MMP7 group had low pCR (25%) and High Rd (74%) in clinical stage T3 pathologic response in contrast to the high pCR (40%) and low residual disease (RD) (60%) of the low MMP7 group.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Hematology

Venetoclax sensitivity in multiple myeloma is associated with B-cell gene expression

Vikas A. Gupta, Benjamin G. Barwick, Shannon M. Matulis, Ryosuke Shirasaki, David L. Jaye, Jonathan J. Keats, Benjamin Oberlton, Nisha S. Joseph, Craig C. Hofmeister, Leonard T. Heffner, Madhav Dhodapkar, Ajay K. Nooka, Sagar Lonial, Constantine S. Mitsiades, Jonathan L. Kaufman, Lawrence H. Boise

Summary: This study found that Venetoclax sensitivity is closely associated with the expression of B-cell genes and genomic features identified in transposase-accessible chromatin sequencing, and there are potential novel biomarkers associated with Venetoclax sensitivity.
Meeting Abstract Hematology

Disrupting Mitohormesis As a Novel Therapeutic Strategy for Multiple Myeloma (MM) Including Those with High Risk Disease and Proteosome Inhibitor Resistance

Serges P. Tsofack, Danielle C. Croucher, Benjamin G. Barwick, Zhihua Li, Ahmed Aman, Dennis Tao, Ellennong Wei, Laura Garcia Prat, Aaron D. Schimmer, Suzanne Trudel

Meeting Abstract Hematology

Disrupting Ectopic Super-Enhancers to Treat Multiple Myeloma

Seth Welsh, Daniel Riggs, Erin Meermeier, Chang-Xin Shi, Victoria Garbitt, Meaghen E. Sharik, Megan Du, Kennedi Todd, Zachary Hammond, Sochilt Brown, Caleb K. Stein, Paola Neri, Nizar J. Bahlis, Benjamin G. Barwick, Larry H. Boise, W. Michael Kuehl, Marta Chesi, P. Leif Bergsagel

Meeting Abstract Hematology

Functional Genomic and Immune Response Characterization of PTEN Loss: Therapeutic Implications for Myeloma

Olga Dashevsky, Ricardo De Matos Simoes, Benjamin G. Barwick, Sara Gandolfi, Ryosuke Shirasaki, Michal Sheffer, Aedin Culhane, Richard Wj Groen, Aviad Tsherniak, Francisca Vazquez, Jonathan D. Licht, Lawrence H. Boise, Constantine S. Mitsiades

Meeting Abstract Hematology

BRAF Mutations and Inflammatory Gene Expression in Myeloma Cells from Patients with Renal Dysfunction

Theodora Alese, Benjamin G. Barwick, Vikas A. Gupta, Nisha Joseph, Craig C. Hofmeister, Mala Shanmugam, Jonathan L. Kaufman, Madhav V. Dhodapkar, Sagar Lonial, Ajay K. Nooka, Lawrence H. Boise

Meeting Abstract Hematology

Functional Oncogenomic and Immune Response Landscape for Genes Recurrently Mutated in Myeloma

Ricardo De Matos Simoes, Benjamin G. Barwick, Ryosuke Shirasaki, Olga Dashevsky, Sara Gandolfi, Huihui Tang, Brian Glassner, Richard W. J. Groen, Daniel Auclair, Aedin Culhane, Aviad Tsherniak, Francisca Vazquez, Jonathan D. Licht, Lawrence H. Boise, Constantine S. Mitsiades

Meeting Abstract Hematology

Mitochondrial Electron Transport Chain Inhibition Promotes Resistance to Proteasome Inhibitors in Multiple Myeloma

Aditi Sharma, Abhinav Achreja, Remya Nair, Pulkit Gupta, Claudia L. Edgar, Olamide Animasahun, Anjali Mitta, Bhakti Dwivedi, Manoj Bhasin, Vikas A. Gupta, Benjamin G. Barwick, Shannon M. Matulis, Sagar Lonial, Lawrence H. Boise, David L. Jaye, Arun P. Wiita, Ajay K. Nooka, Deepak Nagrath, Mala Shanmugam

Letter Hematology

β adrenergic signaling regulates hematopoietic stem and progenitor cell commitment and therapy sensitivity in multiple myeloma

Remya Nair, Vimal Subramaniam, Benjamin G. Barwick, Vikas A. Gupta, Shannon M. Matulis, Sagar Lonial, Lawrence H. Boise, Ajay K. Nooka, Kuzhali Muthumalaiappan, Mala Shanmugam

HAEMATOLOGICA (2022)

Article Oncology

PDZ Proteins SCRIB and DLG1 Regulate Myeloma Cell Surface CD86 Expression, Growth, and Survival

Tyler Moser-Katz, Catherine M. Gavile, Benjamin G. Barwick, Kelvin P. Lee, Lawrence H. Boise

Summary: Despite advances in multiple myeloma treatment, the disease remains incurable. This study reveals the role of CD86 cytoplasmic tail in trafficking CD86 to the cell surface and identifies SCRIB and DLG1 as important proteins for myeloma cell growth and survival.

MOLECULAR CANCER RESEARCH (2022)

Article Oncology

Multivariant Transcriptome Analysis Identifies Modules and Hub Genes Associated with Poor Outcomes in Newly Diagnosed Multiple Myeloma Patients

Olayinka O. Adebayo, Eric B. Dammer, Courtney D. Dill, Adeyinka O. Adebayo, Saheed O. Oseni, Ti'ara L. Griffen, Adaugo Q. Ohandjo, Fengxia Yan, Sanjay Jain, Benjamin G. Barwick, Rajesh Singh, Lawrence H. Boise, James W. Lillard

Summary: This study investigates the molecular mechanisms underlying treatment failures in multiple myeloma using bioinformatic tools. Through gene co-expression network analysis, modules of genes associated with disease survival status were identified and crucial genes within these modules were further studied. The findings reveal the biological functions related to the risk of death in multiple myeloma, providing insights for improving treatment strategies for the disease.

CANCERS (2022)

Letter Oncology

Venetoclax ex vivo functional profiling predicts improved progression-free survival

Vikas A. Gupta, Shannon M. Matulis, Benjamin G. Barwick, R. Devin Bog, Conrad W. Shebelut, Mala Shanmugam, Paola Neri, Nizar J. Bahlis, Madhav V. Dhodapkar, Leonard T. Heffner, Craig C. Hofmeister, Nisha S. Joseph, Sagar Lonial, Jonathan L. Kaufman, David L. Jaye, Ajay K. Nooka, Lawrence H. Boise

BLOOD CANCER JOURNAL (2022)

Article Chemistry, Multidisciplinary

Inhibition of NADPH Oxidase-ROS Signal using Hyaluronic Acid Nanoparticles for Overcoming Radioresistance in Cancer Therapy

Lei Zhu, Yi Zhao, Tongrui Liu, Minglong Chen, Wei Ping Qian, Binghua Jiang, Benjamin G. Barwick, Lumeng Zhang, Toncred M. Styblo, Xiaoxian Li, Lily Yang

Summary: This study developed a bioactive and CD44 targeted hyaluronic acid nanoparticle encapsulated with an NOX inhibitor, GKT831 (HANP/GKT831), resulting in increased sensitivity of breast cancer cells to radiotherapy. By downregulating DNA repair function and oncogenic signal pathways, HANP/GKT831 primed tumor cells for radiation-induced DNA damage and cell death.

ACS NANO (2022)

Article Multidisciplinary Sciences

Therapeutic implications of mitochondrial stress-induced proteasome inhibitor resistance in multiple myeloma

Aditi Sharma, Remya Nair, Abhinav Achreja, Anjali Mittal, Pulkit Gupta, Kamakshi Balakrishnan, Claudia L. Edgar, Olamide Animasahun, Bhakti Dwivedi, Benjamin G. Barwick, Vikas A. Gupta, Shannon M. Matulis, Manoj Bhasin, Sagar Lonial, Ajay K. Nooka, Arun P. Wiita, Lawrence H. Boise, Deepak Nagrath, Mala Shanmugam

Summary: This study reveals the link between metabolic state and therapy resistance in multiple myeloma. Suppression of the electron transport chain increases resistance to proteasome inhibitors. Mitochondrial stress-induced resistance can be alleviated by specific drugs.

SCIENCE ADVANCES (2022)

Meeting Abstract Hematology

IMiDs Synergize with EP300 Inhibition to Disrupt the Ikzf/MYC/IRF4 Axis in Multiple Myeloma

Seth J. Welsh, Benjamin G. Barwick, Erin Meermeier, Daniel Riggs, Chang-Xin Shi, Yuan Xiao Zhu, Meaghen E. Sharik, Megan T. Du, Victoria Marie Garbitt, Caleb K. Stein, Joachim L. Petit, Nathalie Meurice, Rodrigo Fonseca, Kennedi Todd, Sochilt Brown, Yuliza Tafoya Alvarado, Zachary Hammond, Nicklus Cuc, Courtney Wittenberg, Camille Herzog, Lawrence H. Boise, Nizar J. Bahlis, Paola Neri, W. Michael Kuehl, Marta Chesi, P. Leif Bergsagel

Article Immunology

CD8+T cell activation in cancer comprises an initial activation phase in lymph nodes followed by effector differentiation within the tumor

Nataliya Prokhnevska, Maria A. Cardenas, Rajesh M. Valanparambil, Ewelina Sobierajska, Benjamin G. Barwick, Caroline Jansen, Adriana Reyes Moon, Petra Gregorova, Luke delBalzo, Rachel Greenwald, Mehmet Asim Bilen, Mehrdad Alemozaffar, Shreyas Joshi, Cara Cimmino, Christian Larsen, Viraj Master, Martin Sanda, Haydn Kissick

Summary: Improvements in tumor immunotherapies rely on understanding the T cell response to tumors. By studying tumor-draining lymph nodes (TDLNs), it was discovered that activated CD8+ T cells in TDLNs shared characteristics with stem-like cells in tumors. These TDLN cells were revealed to be precursors of tumor-resident stem-like CD8+ T cells. Murine tumor models showed that tumor-specific CD8+ T cells were activated in TDLNs and later differentiated into effector cells in the tumor with co-stimulation.

IMMUNITY (2023)

暂无数据